Apolipoprotein E suppresses the type I inflammatory response in vivo

Circulation Research

Volumn 97, Issue 9, 2005, Pages 922-927

  Ali, Kamilah ^a   Middleton, Melissa ^a,b,c   Puré, Ellen ^b,c   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Apolipoprotein E; Inflammation; Interleukin 12; Lipopolysaccharide; T helper 1

Indexed keywords

APOLIPOPROTEIN E; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; OLIGONUCLEOTIDE; PARASITE ANTIGEN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOXOPLASMA GONDII ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; FEMALE; HOMEOSTASIS; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LIVER; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TH1 CELL; UPREGULATION; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; FEMALE; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; POLY I-C; RNA, MESSENGER; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27644482670     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000187467.67684.43     Document Type: Article

References (27)

1. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprolein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96:2170-2179.
2. Thorngate FE, Rudel LL, Walzern RL, Williams DL. Low levels of extrahepatic nonfnacrophage apoE inhibit atherosclerosis without correcting hypercholesterolemia in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:1939-1945.
3. Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, Maugeais C, Usher DC, Pure E, Rader DJ. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem. 2001;276:261-266.
4. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of normal immunoregulatory lipoprotein, LDL-In. J Immunol. 1986;136:3716-3723.
5. Kelly ME, Clay MA, Mistry MJ, Hsieh LH, Harmony JA. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol. 1994;159:124-139.
6. Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune response to Listeria monocytogenes in vivo. J Lipid Res. 1998;39:1740-1743.
7. De Bont N, Netea MG, Demachr PN, Kullberg BJ, Van Der Meer JW, Stalenhoef AF. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest. 2000;30: 818-822.
8. Van Oosten M, Rensen PCN, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJP, Panel A, Van Berkel TJC, Kuiper J. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J Biol Chem. 2001;276:8820-8824.
9. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. J Pathol. 2003;163:1117-1125.
10. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-γ potentiates atherosclerosis in apoE knock-out mice. J Clin Invest. 1997; 99:2752-2761.
11. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res. 2002;22:661-670.
12. Lee T, Yen H, Pan C, Chau L. The role of interleukin-12 in the development of atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:734-742.
13. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferoh-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000;157:181.9-1824.
14. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:11854-11859.
15. Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech. 2003;14:33-43.
16. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, Kruijt JK, Kuipers F, Van Berkel TJ. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of arterial wall and in the liver. J Biol Chem. 2003;26:23699-23705.
17. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuk M, Yazaki Y, Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 1995;95:469-476.
18. Rensen PCN, Van Oosten M, De Bill E, Van Eck M, Kuiper J, Van Berkel TJC. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest. 1997;99;2438-2445.
19. Read TE, Harris HW, Grunfeld C, Feingold KR, Calhoun MC, Kane JP, Rapp JH. Chylomicrons enhances endotoxin excretion in bile. Infect Immun. 1993;61:3496-3502.
20. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
21. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.
22. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher A. In vivo microbial stimulation induces rapid CD40 ligand-independent, production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med. 1997;186:1819-1829.
23. Butcher BA, Denkers EY. Mechanism of entry determines the ability of Toxoplasma gondii to inhibit macrophage proinflammatory cytokine production. Infect Immun. 2002;70:5216-5224.
24. Bliss SK, Butcher BA, Denkers EY. Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection. J Immunol. 2000; 165:4515-4521.
25. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Muller M, Krause SW, Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003;278:21502-21509.
26. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P, Mantovani A. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998-6004.
27. Kadowaki N, Ho S, Antoneko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.